Three New Compounds from Aspergillus terreus PT06-2 Grown in a High Salt Medium by Wang, Yi et al.
Mar. Drugs 2011, 9, 1368-1378; doi:10.3390/md9081368 
 
Marine Drugs  
ISSN 1660-3397 
www.mdpi.com/journal/marinedrugs 
Communication 
Three New Compounds from Aspergillus terreus PT06-2 Grown 
in a High Salt Medium 
Yi Wang 
†, Jinkai Zheng 
†, Peipei Liu, Wei Wang and Weiming Zhu * 
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, 
Ocean University of China, Qingdao 266003, China; E-Mails: wangyi@hotmail.com (Y.W.); 
zhjk8212@yahoo.cn (J.Z.); liupeipei@ouc.edu.cn (P.L.); wwwakin@ouc.edu.cn (W.W.) 
†  These authors contributed equally to this work. 
*  Author to whom correspondence should be addressed; E-Mail: weimingzhu@ouc.edu.cn;  
Tel./Fax: +86-532-8203-1268. 
Received: 1 June 2011; in revised form: 15 July 2011 / Accepted: 19 July 2011 /  
Published: 12 August 2011  
 
Abstract:  To  investigate  the  structurally  novel  and  bioactive  natural  compounds  from 
marine-derived microorganisms under high salinity, the fungus Aspergillus terreus PT06-2 
was  isolated  from  the  sediment  of  the  Putian  Sea  Saltern,  Fujian,  China.  Three  new 
compounds, terremides A (1) and B (2) and terrelactone A (3), along with twelve known 
compounds (4–15) were isolated and identified from the fermentation broth of A. terreus 
PT06-2 at 10% salinity. Among these metabolites, compounds 4 and 15 only produced in 
the 10% salinity culture, were identified as methyl 3,4,5-trimethoxy-2-(2-(nicotinamido) 
benzamido) benzoate, and (+)-terrein, respectively. The new compounds 1 and 2 exhibited 
antibacterial  activity  against  Pseudomonas  aeruginosa  and  Enterobacter  aerogenes  
with  MIC  values  of  63.9  and  33.5  μM,  respectively.  Compounds  5  showed  moderate  
anti-H1N1 activity and lower cytotoxicity with IC50 and CC50 values of and 143.1 and 
976.4 μM, respectively.  
Keywords: Aspergillus terreus; high salinity metabolites; terremides A and B; terrelactone A 
 
1. Introduction 
Solar salterns matured a surprisingly rich diversity and abundance of halophilic and halotolerant 
fungi [1]. Furthermore, some genes could be activated at high salt concentrations; some new secondary 
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metabolites were probably produced by halotolerant fungi. During pursing the halotolerant microbes 
from hypersaline ecological niches [2–6], Aspergillus terreus PT06-2 was isolated and identified from 
the sediment collected in the Putian Salterns, Fujian, China. A. terreus is commonly isolated from 
cultivated or non-cultivated soils with worldwide distribution and was first published in 1918 [7]. The 
famous  statins  drug  lovastatin,  an  inhibitor  of  3-hydroxy-3-methylglutaryl-coenzyme  A  reductase 
(HMG-CoA reductase), for lowering cholesterol to prevent cardiovascular disease, is mainly produced 
by A. terreus [8,9]. A series of compounds such as terreineol [10], terreulactone A [11], terrain [12], 
terreic acid [13] and aspulvinones [14] were also isolated from this fungus. Chemical screening for 
A. terreus PT06-2 showed that the chemical diversity of the secondary metabolites is the richest at 
10% salinity compared with those at 0% and 3% salt. Chemical investigation in 10% salinity resulted 
in isolation and identification of three new compounds, terremides A and B (1, 2), terrelactone (3), 
along with twelve known compounds (4–15) [15–26]. Antibacterial activity of the new compound 2 
against Enterobacter aerogenes, and the new compound 1 and 4 against Pseudomonas aeruginosa 
were observed. Compound 5 showed moderate anti-H1N1 activity and lower cytotoxicity.  
2. Results and Discussion  
2.1. The Identification of New Metabolites from Aspergillus terreus PT06-2 at 10% Salinity 
Fungus A. terreus PT06-2 was incubated in a high-salt medium containing 10% salt and extracted 
with  EtOAc  to  afford  a  crude  extract.  The  crude  extract  (31.2  g)  was  separated  by  extensive 
chromatography using silica gel, Sephadex LH-20 and HPLC to give compounds 1–15 (Figure 1), 
including three new compounds: terremides A and B (1, 2), terrelactone (3), and twelve known ones: 
methyl  3,4,5-trimethoxy-2-(2-(nicotinamido)benzamido)benzoate  (4)  [15],  (+)-butyrolactones  I–III  
(5–7) [16–19], 3-hydroxy-5-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-4-(4-hydroxyphenyl)-
2(5H)-furanone (8) [20], aspernolide A (9) [16], 5-[(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)-
methyl]-3-hydroxy-4-(4-hydroxyphenyl)-2(5H)-furanone (10) [18], territrem B (11) [22], (−)-(1R,4R)-
1,4-(2,3)-indomethane-1-methyl-2,4-dihydro-1H-pyrazino[2,1-b]quinazoline-3,6-dione  (12)  [23],  
R(−)-6-hydroxymellein (13) [24], trans-4,6-dihydroxymellein (14) [25], and (+)-terrein (15) [26]. 
Terremide  A  (1)  gave  an  HRESIMS  peak  at  m/z  392.1257  [M  +  H]
+  (calcd  for  C21H18N3O5, 
392.1246),  corresponding  to  the  molecular  formula  C21H17N3O5.  The  UV  spectrum  displayed 
absorption at λmax 205 and 262 nm, similar to that of compound 4 [15]. The 1D NMR spectra were  
also  similar  to  those  of  4,  indicating  the  same  molecular  skeleton  [15].  The  differences  were  a  
1,2,3-trisubstituted  benzene  nucleus  instead  of  the  1,2,3,4,5-pentasubstituted  one,  and  the 
corresponding signals of three methoxy groups did not display in the 1D NMR spectra of 1. Besides, 
the  downfield  shifts  for  C-1″–C-3″  were  observed,  suggesting  1  as  the  derivative  of  4  by 
demethoxylation  at  C-4″  and  C-5″,  and  demethylation  at  3″-MeO.  This  deduction  was  further 
supported by the key 
1H-
1H COSY correlations of H-4″/H-5″/H-6″, and the key HMBC correlations 
(Figure 2) form HO-3″ (δH 12.22) to C-3″ (δC 149.8), from H-4″ (δH 7.70) and H-6″ (δH 7.36) to C-2″ 
(δC  128.2),  and  from  CH3O-  (δH  3.95)  to  carbonyl  carbon  (δC  169.2).  Thus,  structure  of  1  was 
determined to be methyl 3-hydroxy-2-(2-(nicotinamido)benzamido)benzoate.  Mar. Drugs 2011, 9  
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Figure 1. Chemical structures of the metabolites (1–15) from A. terreus PT06-2. 
 
Terremide B (2) gave an HRESIMS peak at m/z  374.1160  [M + H]
+  (calcd for C21H16N3O4, 
374.1141), corresponding to the molecular formula C21H15N3O4  that required 16 degrees of 
unsaturation. Compared with compound 1, the molecular formula of 2 is one H2O less and one more 
degree of unsaturation than that of 1. Both 1 and 2 showed similar 
1H and 
13C NMR spectra, except for 
the disappearance of two exchangeable proton signals at δH 11.96/9.08, and the replacement of the 
amido carbon signal at δC 163.7 by a quaternary carbon signal at δC 147.2. Furthermore, another amido 
carbon signal shifted upfield from 169.1 ppm to 160.7 ppm, revealing existence of a quinazolinone 
nucleus [27]. Thus, compound 2 was deduced as the dehydrated and cyclized product of 1. When 
reacted in MeOH, compound 1 formed 2 in 96% yields. Therefore, the structure of terremide B (2) was 
assigned as methyl 3-hydroxy-2-(4-oxo-2-(pyridin-3-yl)quinazolin-3(4H)-yl)benzoate that was further 
determined by X-ray single-crystal diffraction analysis (Figure 2).  
Terrelactone (3) gave an HRESI-MS peak at m/z 465.1529 [M + Na]
+ (calcd for C24H26O8Na, 
465.1525), corresponding to the molecular formula C24H26O8. Its UV spectrum showed characteristic 
absorption of butyrolactones at 231 and 310 nm [21]. 1D NMR showed signals of a 1,2-disubstituted 
benzene nucleus at δH 7.62 (2H, d, 8.2)/6.97 (2H, d, 8.2), a 1,2,4-trisubstituted benzene nucleus at  
δH 6.55 (d, 8.2)/6.51 (brs)/6.52 (d, 8.2), a carbomethoxy at δH/C 3.78/53.7/170.9, and an unsaturated 
butyrolactone at δC 86.0/132.6/139.0/168.7, suggesting the same skeleton as butyrolactone I (5) [18,19]. 
The NMR differences between 3 and 5 were that the signals belonging to the CH=C double band at  
δH/C 5.06/122.4/131.4 in 5 were replaced by a methylene signal at δH/C 1.55/44.4 and a quaternary 
carbon signal at δC 70.2 (Table 1). These data suggested that compound 3 was the hydrated derivative 
of 5 at CH=C double band. This assignment was further supported by 
1H-
1H COSY correlation between Mar. Drugs 2011, 9  
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H-1′′′ and H-2′′′, and HMBC correlations from H-1′′′ to C-2′, C-4′ and C-3′′′, from H-4′′′/5′′′ to C-2′′′ 
and C-3′′′ (Figure 2). The dextral specific rotation ([α]
25
D +71) indicated R-configuration at C-4 [17]. 
Thus, the structure of terrelactone (3) was determined as (R)-methyl 4-hydroxy-2-(4-hydroxy-3- 
(3-hydroxy-3-methylbutyl)benzyl)-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydrofuran-2-carboxylate.  
Figure 2. The key COSY and HMBC correlations for compounds 1 and 3, and the final  
X-ray drawing of compound 2. 
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Table 1. 
1H- and 
13C-NMR (600 and 150 MHz) data for compounds 1–3 in CDCl3. 
Position 
1 
a  2
  3 
b 
δC  δH (J in Hz)  δC  δH (J in Hz)  δC  δH (J in Hz) 
1  119.1, qC    160.7, qC    168.7, qC   
2  140.3, qC    153.4, qC    139.0, qC   
3  122.0, CH  8.87, d (8.3)  147.2, qC    132.6, qC   
4  134.2, CH  7.67, t (7.8)  127.4, CH    86.0, qC   
5  124.0, CH  7.32, t (7.8)  134.8, CH    170.9, qC   
6  128.1, CH  7.99, d (7.8)  127.3, CH  7.79, d (7.9)  39.1, CH2  3.44, s 
7  169.1, qC    126.4, CH  7.92, t (7.9)     
8      120.6, qC  7.61, t (7.9)     
9      131.3, qC  8.16, d (7.9)     
10      147.9, CH       
1′  130.3, qC    150.1, CH    124.8, qC   
2′  148.8, CH  9.26, s  122.5, CH  8.57, s  132.6, CH  6.51, br s 
3′          128.2, qC   
4′  152.6, CH  8.78, d (4.2)  135.0, CH  8.48, d (4.5)  154.8, qC   
5′  123.6, CH  7.45, t “like” (6.0)  160.7, qC  7.29, dd (4.5, 7.9)  115.1, CH  6.52, br d (8.2) 
6′  134.9, CH  8.27, d (6.0)  153.4, qC  7.75, d (7.9)  129.4, CH  6.55, d (8.2) 
7′  163.7, qC           
1″  120.1, qC    124.4, qC    122.8, qC   
2″  128.2, qC    128.7, qC    130.1, CH  7.62, br d (8.2) 
3″  149.8, qC    153.5, qC    116.5, CH  6.97, br d (8.2) 
4″  123.5, CH  7.70, d (7.8)  121.2, CH  7.03, d (7.8)  158.7, qC   
5″  126.7, CH  7.26, t (7.7)  130.0, CH  7.28, t (7.8)  116.5, CH  6.97, br d (8.2) 
6″  126.3, CH  7.36, d (8.2)  120.0, CH  7.33, d (7.8)  130.1, CH  7.62, br d (8.2) 
7″  169.2, qC    165.2, qC       Mar. Drugs 2011, 9  
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Table 1. Cont. 
7″-OMe  53.0, CH3  3.95, s  52.2, CH3  3.65, s     
2-NH    11.96, s         
2″-NH    9.08, s         
3″-OH    12.22, s         
a  The  NMR  data  for  2-NH,  2″-NH  and  3″-OH  are  δH  11.96  (s),  9.08  (s)  and  12.22  (s),  respectively;  
b  Recorded  in  acetone-d6.  The  NMR  data  for  isoprenyl  moiety  and  5-OCH3  are  δH  2.55  (m)/2.45  (m),  
1.55 (2H, m), 1.18 (6H, s), and 3.78 (3H, s), and δC 25.3 (CH2), 44.4 (CH2), 70.2 (CH), 29.8 × 2 (CH3), and 
53.7 (CH3), respectively. 
2.2. The Effects of Salt Stress on Production of Secondary Metabolites from Aspergillus terreus PT06-2 
Salt-tolerant fungi belong to extremophiles which can survive under the conditions of zero to high 
salinity. However, using salt-tolerant fungi to produce new secondary metabolites at high salinity was 
rarely  reported  [2–6].  In  order  to  investigate  the  effect  of  high  salt  stress  on  fungal  secondary 
metabolites, A. terreus PT06-2 was cultured at 0%, 3% and 10% salt. The amount of EtOAc extracts of 
metabolites in 10% salinity was the largest (222 mg vs. 165 and 200 mg of 0% and 3% salinity). The 
chemical diversities of the metabolites in 10% salinity were increased (Figure 3). Compounds 4 and 15 
were not produced by A. terreus PT06-2 when cultivated in 0% and 3% salinity media. The other sole 
secondary metabolites were a kind of red pigments (Figure 3) whose structures were not identified.  
Figure  3. HPLC profiles of secondary metabolites from A. terreus PT06-2 cultured in 
different salt conditions (0%, 3% and 10%, respectively). Peaks circled were red pigments 
(HPLC eluent: 0–60 min, 5–100% CH3OH; flow rate: 1 mL/min). 
 Mar. Drugs 2011, 9  
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2.3. The Bioactivities of Metabolites from Aspergillus terreus PT06-2 in 10% Salinity 
The new compounds (1–3), sole metabolites (4,  15) produced at 10% salinity, and typical 
butyrolactones (5–10) of A. terreus were evaluated for their cytotoxicity against HL-60 and BEL-7402 
cell lines, antimicrobial activity  against  Enterobacter aerogenes,  Pseudomonas aeruginosa, 
Staphylococcus aureus and Candida albicans (Table 2), and antiviral activity against influenza virus 
(H1N1) by MTT [28], agar dilution method [29], and CPE inhibition assay [30,31], respectively. 
Compound  5  showed weak cytotoxicity against HL-60 with an  IC50  (half maximal inhibitory 
concentration) value of 57.5 μM. Compounds 1, 4 and 2 showed weak antibacterial activity against 
S. aureus and E. aerogenes with MIC (minimum inhibitory concentration) of 63.9, 52.4 and 33.5 μM, 
respectively (Table 2). Other compounds did not show cytotoxicity and antibacterial activity (IC50 or 
MIC > 100 μM). Butyrolactone I (5) showed anti-H1N1 activity with IC50 and CC50 (50% cytotoxicity 
concentration) values of 143.1 and 976.4 μM, respectively (positive control: ribavirin, IC50 100.8 μM). 
In addition, it was reported that butyrolactone I (5) showed kinase inhibition with high selectivity 
towards CDK1 and CDK2 [32]. 
Table 2. Antimicrobial activities of compounds 1–4 (“−” indicates not measured). 
Compound  
MIC (μM) 
Enterobacter 
aerogenes 
Pseudomonas 
aeruginosa 
Staphylococcus 
aureus 
Candida 
albicans 
1  >100  >100  63.9  >100 
2  33.5  >100  >100  >100 
3  >100  >100  >100  >100 
4  >100  >100  52.4  >100 
15  >100  >100  >100  >100 
Ciprofloxacin lactate  1  30  1  − 
Ketoconazole  −  −  −  5 
3. Experimental Section  
3.1. General Experimental Procedures  
Optical rotations were obtained on a JASCO P-1020 digital polarimeter. UV spectra were recorded 
on  a  Beckman  DU  640  spectrophotometer.  IR  spectra  were  obtained  on  a  Nicolet  NEXUS  470 
spectrophotometer as KBr disks. 
1H NMR, 
13C NMR, and DEPT spectra and 2D-NMR were recorded 
on a JEOL JNMECP 600 spectrometer using TMS as internal standard, and chemical shifts were 
recorded  as  δ  values.  ESIMS  was  measured  on  a  Q-TOF  Ultima  Global  GAA076  LC  mass 
spectrometer.  Semipreparative  HPLC  was  performed  using  an  ODS  column  (YMC-pack  ODS-A,  
10 × 250 mm, 5 μm, 4 mL/min). HPLC was performed using an ODS column (YMC-pack C18,  
4.6 × 250 mm, 5 μm, 2 mL/min). TLC and column chromatography (CC) were performed on plates 
precoated with silica gel GF254 (10–40 μm) and over silica gel (200–300 mesh, Qingdao Marine 
Chemical  Factory,  Qingdao,  China)  and  Sephadex  LH-20  (Amersham  Biosciences,  Sweden), 
respectively.  All  the  materials  for  the  culture  medium  of  A.  terreus  PT06-2  was  purchased  from 
Qingdao Marine Chemical Factory, Qingdao, China. Mar. Drugs 2011, 9  
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3.2. Fungal Material 
The fungus A. terreus PT06-2 was isolated from sediment (saline 20%), Putian Saltern of Fujian 
Province of China. It was identified according to its morphological characteristics and analyses of its 
18S  rRNA  sequence  (Genbank  JN006059)  by  Prof.  C.  X.  Fang,  China  Center  for  Type  Culture 
Collection. A voucher specimen is deposited in our laboratory at −80 °C. The working strain was 
prepared on potato dextrose agar slants and stored at 4 °C. 
3.3. Fermentation and Extraction  
The fungus A. terreus PT06-2 was grown under static conditions at 28 °C for 35 days in 100 1000-mL 
conical  flasks  containing  liquid  medium  (300  mL/flask,  pH  7.0)  composed  of  glucose  (10  g/L), 
maltose (20 g/L), mannitol (20 g/L), monosodium glutamate (10 g/L), yeast extract (3 g/L), corn steep 
liquor (1 g/L), and 10% salt (NaCl 8%, MgSO4 0.5%, KH2PO4 0.5%, NH4Cl 0.5% and KCl 0.5%). The 
fermented whole broth (30 L) was filtered through cheesecloth to separate the supernatant from the 
mycelia. The supernatant was concentrated under reduced pressure to about 5 L and then extracted 
three times with EtOAc to give an EtOAc solution, while the mycelia were extracted three times with 
acetone. The acetone was removed under reduced pressure to afford a residual aqueous solution. This 
aqueous solution was extracted three times with EtOAc to give a further EtOAc crude extract. Both 
EtOAc solutions were combined and concentrated under reduced pressure to give an extract (31.2 g).  
The fungus A. terreus PT06-2 was incubated under the same conditions in 0%, 3% and 10% salt. 
The chemical diversities of the secondary metabolites of EtOAc extract were investigated with HPLC. 
3.4. Purification  
The extract (31.2 g) from A. terreus PT06-2 was separated into ten fractions (Fraction 1 to 10) on a 
silica gel column using a step gradient elution with CHCl3–petroleum ether (0–100%) and then with 
MeOH–CHCl3 (0–100%). Fraction 4 was separated on Sephadex LH-20 with MeOH–CHCl3 (1:1) and 
100% MeOH to obtain Fraction 4-2 and 4-3. Fraction 4-2 was further purified on semipreparative 
HPLC (60% MeOH) to give compound 15 (106 mg, tR 12 min); Fraction 4-3 was separated on a silica 
gel column using a step gradient elution with Me2CO–petroleum (0–100%) to obtain Fraction 4-3-1 
and 4-3-2. Fraction 4-3-1 was purified on semipreparative HPLC (60% MeOH) to give compound 13  
(7 mg, tR 8 min). Fraction 5 was separated on silica gel column using a step gradient elution with 
Me2CO–petroleum (0–100%) to obtain fraction 5-1 and fraction 5-5. Fraction 5-1 was rechromatographed 
on  silica  gel  column  (MeOH–CHCl3,  1:50),  Sephadex  LH-20  (MeOH–CHCl3,  1:1),  and  then 
semipreparative HPLC (70% MeOH) to give compound 4 (87 mg, tR 8 min), 11 (21 mg, tR 12 min) and 
12 (7 mg, tR 14 min). Fraction 5-5 was chromatographed on Sephadex LH-20 (MeOH-CHCl3, 1:1), 
and then semipreparative HPLC (40% MeOH) to give compound 14 (2 mg, tR 9 min). Fraction 8 was 
separated on Sephadex LH-20 (MeOH-CHCl3, 1:1) twice to obtain Fraction 8-2 and 8-4. Fraction 8-2 
was  chromatographed  on  Sephadex  LH-20  (100%  MeOH),  and  then  semipreparative  HPLC 
(60% MeOH) to give compound 5 (200 mg, tR 23 min), 7 (10 mg, tR 12 min), and 8 (5 mg, tR 18 min). 
Fraction  9  was  separated  on  silica  gel  column  (MeOH–CHCl3,  1:10)  to  obtain  Fraction  9-1–9-4. 
Fraction 9-1 was further purified on semipreparative HPLC (70% MeOH) to give compound 1 (6 mg, Mar. Drugs 2011, 9  
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tR 10 min), 9 (70 mg, tR 12 min), and 10 (4 mg, tR 10 min). Fraction 9-3 was chromatographed on ODS 
column (50% MeOH), and then semipreparative HPLC (60% MeOH) to give compound 2 (3 mg,  
tR 6 min), 6 (3 mg, tR 15 min). Fraction 9-5 was chromatographed on ODS column (40% MeOH), and 
then semipreparative HPLC (60% MeOH) to give compound 3 (45 mg, tR 10 min).  
Terremide A (1): white amorphous powder; UV (MeOH) λmax (log Є) 205 (4.4), 262 (3.2) nm;  
1H and 
13C NMR data, see Table 1; HRESIMS m/z 392.1257 [M + H]
+ (calcd for C21H18N3O5, 392.1246).  
Terremide B (2): colorless crystal; UV (MeOH) λmax (log Є) 212 (4.4), 283 (3.3) nm; 
1H and 
13C NMR data, see Table 1; HRESIMS m/z 374.1160 [M + H]
+ (calcd for C21H16N3O4, 374.1174). 
Terrelactone (3): pale yellow oil; [α]
25
D +71 (c 0.5, CHCl3); UV (MeOH) λmax (log Є) 231 (4.0), 
310 (4.4) nm; IR (KBr) νmax 3275, 2932, 1744, 1703, 1604, 1527, 1433, 1380, 1225, 1146, 839 cm
−1; 
1H 
and 
13C NMR data, see Table 1; HRESIMS m/z 465.1529 [M + Na]
+ (calcd for C24H26O8Na, 465.1525). 
3.5. Chemical Transformation of 1 into 2 
Compound  1  (2  mg,  5 μmol)  was  dissolved  in  MeOH  (0.5  mL)  and  stirred  for  24  h  at  room 
temperature. The reaction mixture was purified by semi-preparative HPLC eluting with 70% CH3OH 
to give compound 2 (1.8 mg, 96% yield) as colorless crystals.  
3.6. X-ray Crystal Structure of 2 
Compound 2 was obtained as colorless monoclinic crystals with molecular formula C21H15N3O4. 
Space group C2/c, a = 27.130 (3) Å, b = 8.9484 (13) Å, c = 14.6147 (17) Å, α = 90.00°, β = 91.248 (2)°, 
γ = 90.00°, V = 3547.2 (8) Å
3, Z = 8, crystal size 0.45 × 0.40 × 0.29 mm
3. A total of 3131 unique 
reflections  (2θ  <  50°)  were  collected  on  a  CCD  area  detector  diffractometer  with  graphite 
monochromated  MoKa  radiation  (λ  =  0.71073  Å).  The  structure  was  solved  by  direct  methods 
(SHELXS-97) and expanded using Fourier techniques (SHELXL-97). The final cycle of full-matrix 
least squares refinement was based on 3131 unique reflections (2θ < 50°) and 254 variable parameters 
and converged with unweighted and weighted agreement factors of R1 = 0.0679, Rw = 0.1074 and  
R = 0.0366 for I > 2sigma(I) data. Crystallographic data (excluding structure factors) for structure 2 in 
this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication  number  CCDC  819714.  Copies  of  the  data  can  be  obtained,  free  of  charge,  on  
application  to  CCDC,  12  Union  Road,  Cambridge  CB2  1EZ,  UK  (Fax:  +44-(0)-1223-336033  or  
E-Mail: deposit@ccdc.cam.ac.uk). 
3.7. Bioassay 
Antimicrobial activity against E. aerogenes, P. aeruginosa, S. aureus and C. albicans was evaluated 
using an agar dilution method [29]. The tested strains were cultivated in LB agar plates for bacteria 
and in YPD agar plates for C. albicans, at 37 °C. Compounds and positive controls were dissolved in 
5% DMSO-H2O at different concentrations from 1000 to 62.5 μg/mL and then from 50 to 0.78 μg/mL, 
using continuous 2-fold dilution. The test solutions (5 μL) were absorbed onto paper disks (5 mm 
diameter) and placed on the assay plates. After 24 h incubation, zones of inhibition (mm in diameter) Mar. Drugs 2011, 9  
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were recorded. The minimum inhibitory concentrations were defined as the lowest concentration at 
which an inhibition zone could be observed. 
Cytotoxicity against HL-60 and BEL-7402 cancer cell lines and confluent MDCK cells was assayed 
by the MTT method [28]. Cell lines were grown in RPMI-1640 supplemented with 10% FBS under a 
humidified atmosphere of 5% CO2 and 95% air at 37 °C. Cell suspensions, 200 μL, at a density of  
5 × 10
4 cell mL
−1 were plated in 96-well microtiter plates and incubated for 24 h. Then, 2 μL of the test 
solutions (in MeOH) were added to each well and further incubated for 72 h. The MTT solution (20 μL, 
5 mg/mL in IPMI-1640 medium) was then added to each well and incubated for 4 h. Old medium 
containing MTT (150 μL) was then gently replaced by DMSO and pipetted to dissolve any formazan 
crystals formed. Absorbance was then determined on a SPECTRA MAX PLUS plate reader at 540 nm. 
The CC50 was calculated as the compound concentration necessary to reduce cell viability by 50%.  
Vp-16 (Etoposide) was used as the positive control with IC50 values of 0.042 and 0.83 μM, respectively.  
The antiviral activity against H1N1 was evaluated by the CPE inhibition assay [30,31]. Confluent 
MDCK  cell  monolayers  were  firstly  incubated  with  influenza  virus  (A/Puerto  Rico/8/34  (H1N1), 
PR/8) at 37 °C for 1 h. After removing the virus dilution, cells were maintained in infecting media 
(RPMI 1640, 4 μg/mL of trypsin) containing different concentrations of test compounds at 37 °C. 
After 48 h incubation at 37 °C, cells were fixed with 100 μL of 4% formaldehyde for 20 min at room 
temperature. After removal of the formaldehyde, the cells were stained with 0.1% crystal violet for 
30 min. The plates were washed and dried, and the intensity of crystal violet staining for each well was 
measured in a microplate reader (Bio-Rad, USA) at 570 nm. The IC50 was calculated as the compound 
concentration required inhibiting influenza virus yield at 48 h post-infection by 50%. Ribavirin was 
used as the positive control with the IC50 values of 100.8 μM. 
4. Conclusions  
In summary, fifteen metabolites including three new compounds were isolated and identified from 
the fermentation broth of A. terreus PT06-2 under 10% salinity conditions. High salt stress affected the 
quantity and profile of secondary metabolites. The new compounds 1 and 2, and the sole metabolite 4 
produced under high salt stress conditions showed antibacterial activity. The typical metabolite of  
A. terreus, butyrolactone I (5), showed anti-H1N1 activity with low cytotoxicity, indicating that 5 
might be a promising drug candidate for anti-influenza virus.  
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